中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
100-100,101
,共2页
腺苷钴胺%三叉神经痛%临床疗效%安全性
腺苷鈷胺%三扠神經痛%臨床療效%安全性
선감고알%삼차신경통%림상료효%안전성
adenosine cobaltamine%trigeminal neuralgia%clinical curative effect%safety
目的：观察腺苷钴胺治疗三叉神经痛的临床疗效及安全性。方法将2012年1月至2015年1月收治的原发性三叉神经痛患者120例随机分为两组，各60例。对照组给予卡马西平常规治疗，观察组在此基础上加用腺苷钴胺肌肉注射，均治疗4周。结果观察组总有效率为95.00％，明显高于对照组的81.67％（ P ＜0.05）；与治疗前比较，治疗后1，2，4周两组患者疼痛对生活质量影响评分均降低（ P＜0.05），治疗后4周观察组降低更显著( P＜0.05）；两组患者头痛、呕吐、眩晕及视物模糊等不良反应发生率无统计学差异（ P＞0.05）；随访半年，观察组复发3例(5.00％)，对照组复发11例（18.33％），观察组复发率显著低于对照组（ P＜0.05）。结论在常规治疗基础上加用腺苷钴胺治疗原发性三叉神经痛，临床疗效明确，能有效缓解疼痛，提高患者生活质量，安全性好，复发率更低。
目的：觀察腺苷鈷胺治療三扠神經痛的臨床療效及安全性。方法將2012年1月至2015年1月收治的原髮性三扠神經痛患者120例隨機分為兩組，各60例。對照組給予卡馬西平常規治療，觀察組在此基礎上加用腺苷鈷胺肌肉註射，均治療4週。結果觀察組總有效率為95.00％，明顯高于對照組的81.67％（ P ＜0.05）；與治療前比較，治療後1，2，4週兩組患者疼痛對生活質量影響評分均降低（ P＜0.05），治療後4週觀察組降低更顯著( P＜0.05）；兩組患者頭痛、嘔吐、眩暈及視物模糊等不良反應髮生率無統計學差異（ P＞0.05）；隨訪半年，觀察組複髮3例(5.00％)，對照組複髮11例（18.33％），觀察組複髮率顯著低于對照組（ P＜0.05）。結論在常規治療基礎上加用腺苷鈷胺治療原髮性三扠神經痛，臨床療效明確，能有效緩解疼痛，提高患者生活質量，安全性好，複髮率更低。
목적：관찰선감고알치료삼차신경통적림상료효급안전성。방법장2012년1월지2015년1월수치적원발성삼차신경통환자120례수궤분위량조，각60례。대조조급여잡마서평상규치료，관찰조재차기출상가용선감고알기육주사，균치료4주。결과관찰조총유효솔위95.00％，명현고우대조조적81.67％（ P ＜0.05）；여치료전비교，치료후1，2，4주량조환자동통대생활질량영향평분균강저（ P＜0.05），치료후4주관찰조강저경현저( P＜0.05）；량조환자두통、구토、현훈급시물모호등불량반응발생솔무통계학차이（ P＞0.05）；수방반년，관찰조복발3례(5.00％)，대조조복발11례（18.33％），관찰조복발솔현저저우대조조（ P＜0.05）。결론재상규치료기출상가용선감고알치료원발성삼차신경통，림상료효명학，능유효완해동통，제고환자생활질량，안전성호，복발솔경저。
Objective To observe the clinical curative effect and safety of adenosine cobaltamine in treating of trigeminal neuralgia. Methods 120 Patients of Primary trigeminal neuralgia in the hosPital between January 2012 and January 2015 were randomly divided into the observation grouP and the control grouP,60 cases in each grouP. The control grouP were given carbamazePine treatment,and the observation grouP were combined with adenosine cobaltamine injections based on the above treatment, for 4 weeks. Results The total effective rate of the observation grouP was 95. 00%, which was higher than 81. 67% of the control grouP ( P < 0. 05 );comPared with before treatment, the Pain on quality of life scores of two grouPs after treatment were both decreased ( P < 0. 05 );4 weeks after treat-ment, the influence of Pain on the quality of life in the observation grouP was significantly lower than the control grouP ( P < 0. 05 );the incidence of adverse reactions in the two grouPs had no statistical difference ( P > 0. 05 );in the follow-uP after 6 months, the re-currence in the observation grouP were 3 Patients ( 5. 00%) which is significanfly lower than 11 Patients ( 18. 33%) in the control grouP ( P < 0. 05 ) . Conclusion Adding adenosine cobaltamine on the conventional treatment in Patients with Primary trigeminal neuralgia treated has clear clinical curative effect, can effectively relieve Pain, imProve the Patient's quality of life with good safety and low reoc-curence rate, and is worth of clinical Promotion.
